Basics Agenus Inc. Agenus Inc along with its subsidiaries is a pharmaceutical company. It is engaged in discovery and development of revolutionary new treatments that engage the body's immune system to benefit patients suffering from cancer. IPO Date: February 4, 2000 Sector: Healthcare Industry: Biotech Market Cap: $140.92M Activated in VL: True Average Daily Range Avg Daily Range: $0.12 | 3.43% Avg Daily Range (30 D): $0.25 | 6.02% Avg Daily Range (90 D): $0.17 | 5.70% Institutional Daily Volume Avg Daily Volume: 1.41M Avg Daily Volume (30 D): 1.18M Avg Daily Volume (90 D): .73M Trade Size Avg Trade Size (Sh.): 283 Avg Trade Size (Sh.) (30 D): 140 Avg Trade Size (Sh.) (90 D): 140 Institutional Trades Total Inst.Trades: 1,266 Avg Inst. Trade: $1.67M Avg Inst. Trade (30 D): $1.01M Avg Inst. Trade (90 D): $1.01M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $1.76M Avg Closing Trade (30 D): $1.07M Avg Closing Trade (90 D): $1.07M Avg Closing Volume: 36.02K     News Jun 13, 2025 @ 1:48 PM Neoantigen Cancer Vaccines Industry Analysis Repor... Source: Researchandmarkets.Com Feb 12, 2025 @ 6:00 PM MiNK Therapeutics to Present Updated Data from Pha... Source: N/A Jan 23, 2025 @ 7:13 PM MiNK Therapeutics Targets Immune Reconstitution to... Source: N/A Nov 12, 2024 @ 5:15 PM Agenus (AGEN) Q3 2024 Earnings Call Transcript Source: The Motley Fool Nov 2, 2024 @ 11:45 AM DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages In... Source: Faruqi & Faruqi, Llp Financials   TTM Q4 2024 FY 2024 Basic EPS $-10.59 $-1.94 $-10.59 Diluted EPS $-10.59 $-1.94 $-10.59 Revenue $ 103.46M $ 26.84M $ 103.46M Gross Profit $ 102.98M $ 26.72M $ 102.98M Net Income / Loss $ -232.27M $ -46.81M $ -232.27M Operating Income / Loss $ -120.48M $ -25.9M $ -120.48M Cost of Revenue $ .49M $ .12M $ .49M Net Cash Flow $ -35.45M $ -4.3M $ -35.45M PE Ratio     Splits Apr 12, 2024:   1:20 Oct 03, 2011:   1:6